Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment for adults with high-risk, HER2-negative early breast cancer and a deleterious or suspected deleterious germline BRCA mutation after neoadjuvant or adjuvant chemotherapy.
LAMPGEN ANALYSIS
Why it matters
This brings PARP inhibition to an early breast cancer setting defined by inherited BRCA status and risk.
What research teams should watch
Verify germline testing and document high-risk features, local treatment, and prior chemotherapy.
PRIMARY RECORDS